Mechanism of PDZK1 in Hepatocellular Carcinoma Complicated with Hyperuricemia.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
08
2022
revised:
27
09
2022
accepted:
11
10
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
25
11
2022
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is a kind of primary liver cancer that accounts for more than 90% of primary hepatocellular carcinomas. Hyperuricemia is closely related to the development, recurrence, metastasis, and prognosis of cancer. Previous studies have proved that the serum uric acid level can increase the incidence rate and mortality of malignant tumors. However, the specific pathogenesis remains unstudied. RT-qPCR analysis showed that the mRNA expression of PDZK1 and ABCG2 increased significantly after HCC cells were exposed to different concentrations of soluble uric acid (2.5, 5, 10, 20 mg/dl) for 24 hours. Then, in HCC shRNAs, PDZK1, or over expression PDZK1 were used. CCK8, wound healing, and Transwell assay showed that PDZK1 regulates cell proliferation, invasion, and migration. Flow cytometry results revealed that PDZK1 affects cell apoptosis. Western blot results show that PDZK1 affects the STAT3/C-myc pathway. Then, in vivo tumorigenesis, allopurinol maybe an effective drug to advance: the prognosis of HCC. In our study, RT-qPCR analysis showed that the mRNA expression of PDZK1 and ABCG2 increased significantly after different concentrations of soluble uric acid in HCC. Then, PDZK1 affects the proliferation, migration, and apoptosis of HCC through the STAT3/C-myc pathway. Hyperuricemia response affects the expression of PDZK1; PDZK1 affects the proliferation, migration, and apoptosis through the STAT3/C-myc pathway in hepatocellular carcinoma. It is suggested that PDZK1 maybe closely related to the occurrence, development, and prognosis of HCC and allopurinol maybe have potential anticancer effects.
Sections du résumé
Background
UNASSIGNED
Hepatocellular carcinoma (HCC) is a kind of primary liver cancer that accounts for more than 90% of primary hepatocellular carcinomas. Hyperuricemia is closely related to the development, recurrence, metastasis, and prognosis of cancer. Previous studies have proved that the serum uric acid level can increase the incidence rate and mortality of malignant tumors. However, the specific pathogenesis remains unstudied.
Methods
UNASSIGNED
RT-qPCR analysis showed that the mRNA expression of PDZK1 and ABCG2 increased significantly after HCC cells were exposed to different concentrations of soluble uric acid (2.5, 5, 10, 20 mg/dl) for 24 hours. Then, in HCC shRNAs, PDZK1, or over expression PDZK1 were used. CCK8, wound healing, and Transwell assay showed that PDZK1 regulates cell proliferation, invasion, and migration. Flow cytometry results revealed that PDZK1 affects cell apoptosis. Western blot results show that PDZK1 affects the STAT3/C-myc pathway. Then, in vivo tumorigenesis, allopurinol maybe an effective drug to advance: the prognosis of HCC.
Results
UNASSIGNED
In our study, RT-qPCR analysis showed that the mRNA expression of PDZK1 and ABCG2 increased significantly after different concentrations of soluble uric acid in HCC. Then, PDZK1 affects the proliferation, migration, and apoptosis of HCC through the STAT3/C-myc pathway.
Conclusions
UNASSIGNED
Hyperuricemia response affects the expression of PDZK1; PDZK1 affects the proliferation, migration, and apoptosis through the STAT3/C-myc pathway in hepatocellular carcinoma. It is suggested that PDZK1 maybe closely related to the occurrence, development, and prognosis of HCC and allopurinol maybe have potential anticancer effects.
Identifiants
pubmed: 36420358
doi: 10.1155/2022/1403454
pmc: PMC9678461
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1403454Informations de copyright
Copyright © 2022 Linqi Guo et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Pathophysiology. 2021 Aug 31;28(3):387-399
pubmed: 35366282
J Hepatol. 2021 Oct;75(4):865-878
pubmed: 33992698
Redox Biol. 2019 Feb;21:101070
pubmed: 30576922
Int J Clin Exp Med. 2015 Aug 15;8(8):13911-8
pubmed: 26550347
Cancer Res. 2000 Nov 15;60(22):6367-75
pubmed: 11103799
PLoS One. 2015 Jan 24;10(1):e0116714
pubmed: 25617895
Med Clin (Barc). 2020 Dec 24;155(12):521-528
pubmed: 32430206
Prostate Cancer Prostatic Dis. 2018 Sep;21(3):373-378
pubmed: 29273728
Mol Clin Oncol. 2017 Apr;6(4):589-592
pubmed: 28413674
Open Rheumatol J. 2018 Jul 24;12:94-113
pubmed: 30123371
Expert Rev Gastroenterol Hepatol. 2021 Nov;15(11):1295-1307
pubmed: 34624198
Hematol Oncol. 2019 Dec;37(5):537-547
pubmed: 31461568
J Proteome Res. 2012 Nov 2;11(11):5135-44
pubmed: 23057591
J Gastrointestin Liver Dis. 2020 Jun 03;29(2):175-179
pubmed: 32530984
Arthritis Res Ther. 2018 Feb 07;20(1):20
pubmed: 29415757
PLoS Pathog. 2010 Oct 07;6(10):e1001130
pubmed: 20949066
Medicine (Baltimore). 2020 Nov 06;99(45):e22632
pubmed: 33157919
Postgrad Med J. 2020 Feb;96(1132):102
pubmed: 31292278
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Free Radic Res. 2021 Jul;55(7):810-820
pubmed: 34278932
Arch Cardiol Mex. 2021 Jul 14;92(2):253-263
pubmed: 34261129
Leuk Res. 2020 Feb;89:106298
pubmed: 31945598
Mol Cancer Res. 2008 Dec;6(12):1852-60
pubmed: 19074830
Biochim Biophys Acta Biomembr. 2018 May;1860(5):973-980
pubmed: 29317200
Oncogene. 2017 Nov 2;36(44):6119-6131
pubmed: 28692056
Phytomedicine. 2020 Jan;66:153111
pubmed: 31790902
JHEP Rep. 2020 Jan 20;2(2):100067
pubmed: 32118201
Leuk Lymphoma. 2020 Dec;61(12):2923-2930
pubmed: 32654590
Leuk Lymphoma. 2020 Jul;61(7):1744-1747
pubmed: 32096431
World J Gastroenterol. 2017 Sep 28;23(36):6571-6592
pubmed: 29085206
J Hepatol. 2022 Feb;76(2):446-457
pubmed: 34555422
Acta Pharmacol Sin. 2022 Jul;43(7):1623-1632
pubmed: 34811515
Int Urol Nephrol. 2017 Sep;49(9):1611-1620
pubmed: 28210913
Muscles Ligaments Tendons J. 2014 Nov 17;4(3):292-7
pubmed: 25489545
Cancer Lett. 2019 Jul 1;453:107-121
pubmed: 30930234
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Am Coll Cardiol. 2022 May 3;79(17):1757-1780
pubmed: 35379504
Cureus. 2018 Mar 28;10(3):e2382
pubmed: 29850377
Evid Based Complement Alternat Med. 2017;2017:1640187
pubmed: 28133487
J Food Sci. 2021 Jul;86(7):3265-3276
pubmed: 34160066
Croat Med J. 2010 Feb;51(1):23-31
pubmed: 20162742